Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma.
| dc.contributor.author | Dequen, P | |
| dc.contributor.author | Lorigan, Paul C | |
| dc.contributor.author | Jansen, J | |
| dc.contributor.author | van Baardewijk, M | |
| dc.contributor.author | Ouwens, M | |
| dc.contributor.author | Kotapati, S | |
| dc.date.accessioned | 2013-03-22T13:57:46Z | |
| dc.date.available | 2013-03-22T13:57:46Z | |
| dc.date.issued | 2012 | |
| dc.identifier.citation | Systematic review and network meta-analysis of overall survival comparing 3 mg/kg Ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. 2012, 17 (11):1376-85 Oncologist | en_GB |
| dc.identifier.issn | 1549-490X | |
| dc.identifier.pmid | 23024154 | |
| dc.identifier.doi | 10.1634/theoncologist.2011-0427 | |
| dc.identifier.uri | http://hdl.handle.net/10541/275684 | |
| dc.description.abstract | To compare the overall survival (OS) of patients treated with 3 mg/kg ipilimumab versus alternative systemic therapies in pretreated unresectable stage III or IV melanoma patients. | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to The oncologist | en_GB |
| dc.title | Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. | en |
| dc.type | Article | en |
| dc.contributor.department | MAPI Group, Houten, The Netherlands. | en_GB |
| dc.identifier.journal | The Oncologist | en_GB |
| html.description.abstract | To compare the overall survival (OS) of patients treated with 3 mg/kg ipilimumab versus alternative systemic therapies in pretreated unresectable stage III or IV melanoma patients. |